Quarterly ResultMay 14, 2026, 12:26 PM
Regen BioPharma Reports Q1 Net Profit $991,927; Going Concern Doubt
AI Summary
Regen BioPharma Inc. reported a net profit of $991,927 for the quarter ended March 31, 2026, a significant improvement from a net loss of $19,354 in the prior year quarter, primarily driven by derivative income. For the six months, the company posted a net profit of $24,074, compared to a loss of $534,739 in the previous year. However, the company's cash balance plummeted to $271, and it continues to face substantial doubt about its ability to continue as a going concern due to accumulated deficits and ongoing operational losses.
Key Highlights
- Net profit for Q1 2026 was $991,927, a significant improvement from a $19,354 loss in Q1 2025.
- Net profit for the six months ended March 31, 2026, was $24,074, compared to a $534,739 loss in the prior year.
- Cash balance decreased significantly to $271 as of March 31, 2026, from $69,555 in September 2025.
- Total operating expenses for the six months increased to $823,462 from $292,857 year-over-year.
- Net cash used in operating activities for the six months increased to $261,175 from $167,609.
- Accumulated deficit stands at $21,667,546 as of March 31, 2026.
- Company faces substantial doubt about its ability to continue as a going concern.